TEAs Fail To Sweeten OTC Monograph Process, Brew Trouble For New Ingredients
This article was originally published in The Tan Sheet
Executive Summary
The TEA option has not provided a more efficient and less costly method for drug industry stakeholders to convince FDA to expand OTC monographs with ingredients that have demonstrated safety records in foreign markets, but a system that rivals the rigors of the new drug application process.